Congestive Heart Failure (Heart Failure) - Global Clinical Trials Review, 2026
Summary
The analyst's clinical trial report, “Congestive Heart Failure (Heart Failure) - Global Clinical Trials Review, 2026" provides an overview of Congestive Heart Failure (Heart Failure) Clinical trials scenario. This report provides top line data relating to the clinical trials on Congestive Heart Failure (Heart Failure). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The Analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Congestive Heart Failure (Heart Failure) to Cardiovascular Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Congestive Heart Failure (Heart Failure) to Cardiovascular Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Congestive Heart Failure (Heart Failure)
- Sep 07, 2026: Novo Nordisk’s ziltivekimab stumbles again on pair of Phase III terminations
- Sep 01, 2026: ESC 2026: AstraZeneca’s oral relaxin agonist succeeds in Phase II trial
- Aug 31, 2026: Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results in Patients With Recent Worsening Heart Failure
- Aug 29, 2026: AskBio Presents Baseline Characteristics from Phase 2 Heart Failure Gene Therapy Trial of Umiposgene Parvec (AB-1002) at ESC Congress
- Aug 27, 2026: Cardurion Pharmaceuticals Announces Late-Breaking Presentation of Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, in Heart Failure
- Aug 20, 2026: Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026
- Aug 12, 2026: DR10624 Selected for 2026 National Science and Technology Major Project "Innovative Drug Development for Heart Failure
- Aug 10, 2026: Tenax Therapeutics Announces Topline Results From Phase 3 LEVEL Clinical Trial of TNX-103 in Patients With PH-HFpEF
- Jul 29, 2026: ANVISA approves treatment for type of heart failure that had few effective options; deaths and hospitalizations drop significantly
- Jul 13, 2026: Huadong Medicine Has Received IND Approval of DR10624, Used to Treat Adult Heart Failure With Preserved/Mildly Reduced Ejection Fraction
- Jul 02, 2026: Tenax Therapeutics Announces Late-Breaking Presentation of Level Clinical Trial Data at ESC Congress 2026
- Clinical Trial Profile Snapshots
- Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact Us
- Source
- Congestive Heart Failure (Heart Failure) Therapeutics, Global, Clinical Trials by Region, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Europe, Top Five Countries, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, North America, Top Countries, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2026*
- Proportion of Congestive Heart Failure (Heart Failure) to Cardiovascular Clinical Trials, G7 Countries (%), 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Congestive Heart Failure (Heart Failure) to Cardiovascular Clinical Trials, E7 Countries (%), 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, Global, Clinical Trials by Phase, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, Global, Clinical Trials In Progress by Phase 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Congestive Heart Failure (Heart Failure) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, Global, Clinical Trials by Region (%), 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, North America, Top Countries (%), 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2026*
- Proportion of Congestive Heart Failure (Heart Failure) to Cardiovascular Clinical Trials, G7 Countries (%), 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Congestive Heart Failure (Heart Failure) to Cardiovascular Clinical Trials, E7 Countries (%), 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, Global, Clinical Trials by Phase (%), 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, Global, Clinical Trials In Progress by Phase, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Congestive Heart Failure (Heart Failure) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Congestive Heart Failure (Heart Failure) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- The Analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Novartis AG
- AstraZeneca Plc
- C. H. Boehringer Sohn AG & Co KG
- Bristol-Myers Squibb Co
- Johnson & Johnson
- Merck & Co Inc
- Otsuka Holdings Co Ltd
- Pfizer Inc
- Parexel International Corp
